CSL Limited (CSL.AX)
| Previous close | 288.61 |
| Open | 287.64 |
| Bid | 288.00 x 0 |
| Ask | 288.96 x 0 |
| Day's range | 287.16 - 289.70 |
| 52-week range | 228.65 - 313.55 |
| Volume | |
| Avg. volume | 659,800 |
| Market cap | 139.902B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 36.48 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.97 (1.38%) |
| Ex-dividend date | 09 Sept 2024 |
| 1y target est | N/A |
- PR Newswire
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). This latest acquisition of pre-pandemic vaccine will further supplement BARDA's stockpile of vaccine
- PR Newswire
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
CSL Seqirus, a business of CSL (ASX: CSL), today announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health. The data are being presented in an oral presentation and poster sessions at OPTIONS for the Control of Influenza (OPTIONS XII), being held in Brisbane, Australia from September 29 to October 2, 2024.
- Business Wire
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
WALTHAM, Mass. & SAN DIEGO, September 30, 2024--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty® for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dos
